Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
1.
Arthritis Rheumatol ; 75(5): 645-649, 2023 05.
Article in English | MEDLINE | ID: covidwho-2318790
2.
Am J Med Sci ; 364(5): 538-546, 2022 Nov.
Article in English | MEDLINE | ID: covidwho-1914120

ABSTRACT

BACKGROUND: Little is known about satisfaction with different modes of telemedicine delivery. The objective of this study was to determine whether patient satisfaction with phone-only was noninferior to video visits. METHODS: We conducted a parallel group, randomized (1:1), single-blind, noninferiority trial in multispecialty clinics at a tertiary academic medical center. Adults age ≥ 60 years or with Medicare/Medicaid insurance were eligible. Primary outcome was visit satisfaction rate (9 or 10 on a 0-10 satisfaction scale). Noninferiority was determined if satisfaction with phone-only (intervention) versus video visits (comparator) was no worse by a -15% prespecified noninferiority margin. We performed modified intent-to-treat (mITT) and per protocol analyses, after adjusting for age and insurance. RESULTS: 200 participants, 43% Black, 68% women completed surveys. Visit satisfaction rates were high. In the mITT analysis, phone-only visits were noninferior by an adjusted difference of 3.2% (95% CI, -7.6% to 14%). In the per protocol analysis, phone-only were noninferior by an adjusted difference of -4.1% (95% CI, -14.8% to 6.6%). The proportion of participants who indicated they preferred the same type of telemedicine visit as their next clinic visit were similar (30.2% vs 27.9% video vs phone-only, p = 0.78) and a majority said their medical concerns were addressed and would recommend a telemedicine visit. CONCLUSIONS: Among a group of diverse, established older or underserved patients, the satisfaction rate for phone-only was noninferior to video visits. These findings could impact practice and policies governing telemedicine.


Subject(s)
COVID-19 , Telemedicine , Humans , Aged , United States , Adult , Female , Middle Aged , Male , COVID-19/epidemiology , Single-Blind Method , Personal Satisfaction , Medicare , Telemedicine/methods
4.
Arthritis Care Res (Hoboken) ; 73(8): 1153-1161, 2021 08.
Article in English | MEDLINE | ID: covidwho-1298444

ABSTRACT

OBJECTIVE: The effect of the COVID-19 pandemic on community-based rheumatology care and the use of telehealth is unclear. We undertook this study to investigate the impact of the pandemic on rheumatology care delivery in a large community practice-based network. METHODS: Using a community practice-based rheumatologist network, we examined trends in in-person versus telehealth visits versus canceled visits in 3 time periods: pre-COVID-19, COVID-19 transition (6 weeks beginning March 23, 2020), and post-COVID-19 transition (May-August). In the transition period, we compared patients who received in-person care versus telehealth visits versus those who cancelled all visits. We used multivariable logistic regression to identify factors associated with canceled or telehealth visits. RESULTS: Pre-COVID-19, there were 7,075 visits/week among 60,002 unique rheumatology patients cared for by ~300 providers practicing in 92 offices. This number decreased substantially (24.6% reduction) during the COVID-19 transition period for in-person visits but rebounded to pre-COVID-19 levels during the post-COVID-19 transition. There were almost no telehealth visits pre-COVID-19, but telehealth increased substantially during the COVID-19 transition (41.4% of all follow-up visits) and slightly decreased during the post-COVID-19 transition (27.7% of visits). Older age, female sex, Black or Hispanic race/ethnicity, lower socioeconomic status, and rural residence were associated with a greater likelihood of canceling visits. Most factors were also associated with a lower likelihood of having telehealth versus in-office visits. Patients living further from the rheumatologists' office were more likely to use telehealth. CONCLUSION: COVID-19 led to large disruptions in rheumatology care; these disruptions were only partially offset by increases in telehealth use and disproportionately affected racial/ethnic minorities and patients with lower socioeconomic status. During the COVID-19 era, telehealth continues to be an important part of rheumatology practice, but disparities in access to care exist for some vulnerable groups.


Subject(s)
COVID-19/epidemiology , Community Health Services/trends , Office Visits/trends , Patient Acceptance of Health Care , Rheumatology/trends , Telemedicine/trends , Adult , Aged , COVID-19/prevention & control , Delivery of Health Care/trends , Female , Follow-Up Studies , Humans , Longitudinal Studies , Male , Middle Aged
5.
Arthritis Rheumatol ; 73(3): 548-549, 2021 03.
Article in English | MEDLINE | ID: covidwho-1198365
6.
Arthritis Rheumatol ; 72(8): 1241-1251, 2020 08.
Article in English | MEDLINE | ID: covidwho-602110

ABSTRACT

OBJECTIVE: To provide guidance to rheumatology providers on the management of adult rheumatic disease in the context of the coronavirus disease 2019 (COVID-19) pandemic. METHODS: A task force, including 10 rheumatologists and 4 infectious disease specialists from North America, was convened. Clinical questions were collated, and an evidence report was rapidly generated and disseminated. Questions and drafted statements were reviewed and assessed using a modified Delphi process. This included 2 rounds of asynchronous anonymous voting by e-mail and 3 webinars with the entire panel. Task force members voted on agreement with draft statements using a 1-9-point numerical scoring system, and consensus was determined to be low, moderate, or high based on the dispersion of votes. For approval, median votes were required to meet predefined levels of agreement (median values of 7-9, 4-6, and 1-3 defined as agreement, uncertainty, or disagreement, respectively) with either moderate or high levels of consensus. RESULTS: The task force approved 77 initial guidance statements: 36 with moderate and 41 with high consensus. These were combined, resulting in 25 final guidance statements. CONCLUSION: These guidance statements are provided to promote optimal care during the current pandemic. However, given the low level of available evidence and the rapidly evolving literature, this guidance is presented as a "living document," and future updates are anticipated.


Subject(s)
Antirheumatic Agents/therapeutic use , Coronavirus Infections/epidemiology , Glucocorticoids/therapeutic use , Immunosuppressive Agents/therapeutic use , Pneumonia, Viral/epidemiology , Rheumatic Diseases/drug therapy , Adult , Advisory Committees , Angiotensin Receptor Antagonists/therapeutic use , Angiotensin-Converting Enzyme Inhibitors/therapeutic use , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Betacoronavirus , COVID-19 , Coronavirus Infections/complications , Coronavirus Infections/prevention & control , Delivery of Health Care , Delphi Technique , Deprescriptions , Humans , Hydroxychloroquine/therapeutic use , Infection Control , Janus Kinase Inhibitors/therapeutic use , Pandemics/prevention & control , Pneumonia, Viral/complications , Pneumonia, Viral/prevention & control , Rheumatic Diseases/complications , Rheumatology , SARS-CoV-2 , Tumor Necrosis Factor Inhibitors/therapeutic use
8.
Arthritis Rheumatol ; 73(2): e1-e12, 2021 02.
Article in English | MEDLINE | ID: covidwho-985949

ABSTRACT

OBJECTIVE: To provide guidance to rheumatology providers on the management of adult rheumatic disease in the context of the coronavirus disease 2019 (COVID-19) pandemic. METHODS: A task force, including 10 rheumatologists and 4 infectious disease specialists from North America, was convened. Clinical questions were collated, and an evidence report was rapidly generated and disseminated. Questions and drafted statements were reviewed and assessed using a modified Delphi process. This included asynchronous anonymous voting by email and webinars with the entire panel. Task force members voted on agreement with draft statements using a 1-9-point numerical scoring system, and consensus was determined to be low, moderate, or high based on the dispersion of votes. For approval, median votes were required to meet predefined levels of agreement (median values of 7-9, 4-6, and 1-3 defined as agreement, uncertainty, or disagreement, respectively) with either moderate or high levels of consensus. RESULTS: Draft guidance statements approved by the task force have been combined to form final guidance. CONCLUSION: These guidance statements are provided to promote optimal care during the current pandemic. However, given the low level of available evidence and the rapidly evolving literature, this guidance is presented as a "living document," and future updates are anticipated.


Subject(s)
Antirheumatic Agents/therapeutic use , COVID-19/prevention & control , Glucocorticoids/administration & dosage , Immunosuppressive Agents/therapeutic use , Rheumatic Diseases/therapy , Advisory Committees , COVID-19/complications , Consensus , Decision Making, Shared , Delivery of Health Care , Delphi Technique , Deprescriptions , Disease Management , Humans , Patient Education as Topic , Rheumatic Diseases/complications , Rheumatology , SARS-CoV-2 , Societies, Medical
SELECTION OF CITATIONS
SEARCH DETAIL